SCHEMBL4932467

SCHEMBL4932467

O=Cc1c[nH]c2c(OCc3ccccc3)cccc12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.59
PLA2G2A P14555 1/20 0.59
TRPM8 Q7Z2W7 1/20 0.59
TRIM24 O15164 1/20 0.50
TRIM33 Q9UPN9 1/20 0.50
MAPT P10636 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
CCNB2 O95067 1/20 0.48
CDK1 P06493 1/20 0.48
CDK4 P11802 1/20 0.48
CCNB1 P14635 1/20 0.48
CCND1 P24385 1/20 0.48
CCNB3 Q8WWL7 1/20 0.48
PIM1 P11309 4/20 0.46
PIM3 Q86V86 4/20 0.46
PIM2 Q9P1W9 1/20 0.46
MAPK1 P28482 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15323209 0.84 PTGER4 (0.62) LTA4HPLA2G2ATRPM8PTGER1PTGER4
SCHEMBL15323207 0.84 PTGER4 (0.62) LTA4HPLA2G2ATRPM8PTGER1PTGER4
SCHEMBL9023220 0.84 LTA4H (0.44) LTA4HPLA2G2ATRPM8TRIM24TRIM33
SCHEMBL29952932 0.81 TRIM24 (0.58) TRIM24TRIM33MAPTSMN1; SMN2PIM1
SCHEMBL7835758 0.81 ERN1 (0.43) LTA4HPLA2G2ATRPM8TRIM24TRIM33
SCHEMBL8304176 0.81 L3MBTL1 (0.48) LTA4HPLA2G2ATRPM8MAPTL3MBTL1
SCHEMBL16589531 0.80 MAP3K7 (0.57) LTA4HPLA2G2ATRPM8MAPTPTGER1
SCHEMBL29955611 0.80 PIM1 (0.50) LTA4HPLA2G2ATRPM8TRIM24TRIM33
SCHEMBL16714058 0.79 LTA4H (0.60) LTA4HPLA2G2ATRPM8MAPTL3MBTL1
SCHEMBL5646738 0.79 LTA4H (0.48) LTA4HPLA2G2ATRPM8MAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
US-20220024870-A1 Synthesis of (S)-6-Hydroxytryptophan and Derivatives Thereof HEIDELBERG PHARMA RESEARCH GMBH (DE) 2022-01-27 US disclosed
WO-2020120525-A1 SYNTHESIS OF (S)-6-HYDROXYTRYPTOPHAN AND DERIVATIVES THEREOF HEIDELBERG PHARMA RESEARCH GMBH (DE) 2020-06-18 WO disclosed
US-9499484-B2 Indole, indoline derivatives, compositions comprising them and uses thereof YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) 2016-11-22 US disclosed
US-9499484-B2 Indole, indoline derivatives, compositions comprising them and uses thereof YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) 2016-11-22 US disclosed
US-9499484-B2 Indole, indoline derivatives, compositions comprising them and uses thereof YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) 2016-11-22 US disclosed
CN-103391936-B Carcinostatic agent THE UNIVERSITY OF TOKYO (JP) 2016-04-27 CN disclosed
EP-2565192-B9 ANTICANCER AGENT UNIV TOKYO (JP) 2015-11-25 EP disclosed
US-9156827-B2 Anticancer agent THE UNIVERSITY OF TOKYO (JP) 2015-10-13 US disclosed
EP-2565192-B1 ANTICANCER AGENT UNIV TOKYO (JP) 2015-08-12 EP disclosed
US-20070149603-A1 PPAR ACTIVE COMPOUNDS PLEXXIKON, INC. 2007-06-28 US disclosed
US-20020115700-A1 Substituted indole compounds and methods of their use CHIN ALLISON C (US) 2002-08-22 US disclosed
US-6372742-B1 TELOMERASE ENZYME INHIBITORS AND ANTICANCER AGENTS GERON CORPORATION 2002-04-16 US disclosed
EP-1109808-A1 SUBSTITUTED INDOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER Geron Corporation (US) 2001-06-27 EP disclosed
WO-2001002394-A1 SUBSTITUTED INDOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER GERON CORPORATION (US) 2001-01-11 WO disclosed
EP-0548250-B1 SUBSTITUTED BICYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B4 ANTAGONIST ACTIVITY RHONE POULENC RORER INT (US) 1996-03-27 EP disclosed
US-5468898-A Substituted naphthylene compounds exhibiting selective leukotriene B4 antagonist activity RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1995-11-21 US disclosed
EP-0548250-A4 SUBSTITUTED BICYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B 4? ANTAGONIST ACTIVITY 1993-10-27 EP disclosed
EP-0548250-A1 SUBSTITUTED BICYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B 4? ANTAGONIST ACTIVITY. RHONE POULENC RORER INT (US) 1993-06-30 EP disclosed
WO-1992004321-A1 SUBSTITUTED BICYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B4 ANTAGONIST ACTIVITY RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) 1992-03-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220024870-A1 Synthesis of (S)-6-Hydroxytryptophan and Derivatives Thereof AANAT, HNMT, HTR6 LTA4H 534/4885PLA2G2A 1249/4885TRPM8 2133/4885
US-20020115700-A1 Substituted indole compounds and methods of their use TERT, INMT, POT1 LTA4H 2158/4885PLA2G2A 4313/4885TRPM8 4507/4885
US-20070149603-A1 PPAR ACTIVE COMPOUNDS PPARG, PPARD, PPARA LTA4H 1284/4885PLA2G2A 938/4885TRPM8 921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.